Madoka Kondo, Takayasu Mori, Tadashi Oshita, Atsuki Ohashi, Eisei Sohara, Shinichi Uchida, Yoshitaka Maeda
8 min
Chronic kidney disease (CKD) often has an underlying genetic component, with hereditary conditions becoming increasingly recognized as major contributors to end-stage kidney disease (ESKD). While Intersectin 2 (ITSN2) has been previously identified as a cause of steroid-sensitive nephrotic syndrome, reported cases are rare. This study examines a 52-year-old Japanese woman presenting with progressive renal dysfunction, mild proteinuria, hematuria, and a strong family history of ESKD, aiming to determine the clinical significance of a rare heterozygous ITSN2 variant in the absence of typical nephrotic symptoms.
Clinical assessment over seven years showed a steady decline in renal function, with serum creatinine rising from 1.15 to 1.79 mg/dL. Renal biopsy revealed significant glomerular sclerosis (37.5% of glomeruli) and thinning of the basement membrane (TBM), but no evidence of immune complex deposition or typical podocyte damage associated with nephrotic syndrome. Comprehensive genetic screening for 121 inherited kidney disease genes, including those responsible for Alport syndrome (COL4A3/4/5), was negative, but did uncover a single heterozygous variant in the ITSN2 gene (p.Ser339Cys).
ITSN2 is a multi-domain protein crucial for actin assembly and endocytic membrane trafficking. The authors hypothesize that the identified ITSN2 variant may impair the activation of CDC42—a Rho GTPase essential for maintaining the glomerular actin cytoskeleton. Furthermore, the patient exhibited significant accelerated atherosclerosis, such as carotid plaque and aortic calcification, which the authors speculate may be linked to impaired CDC42 signaling. This suggests that ITSN2 variants might drive renal failure through mechanisms involving basement membrane fragility and vascular dysfunction rather than just acute podocyte injury.
This case highlights the clinical heterogeneity of ITSN2-related kidney disease. It expands the phenotypic spectrum of ITSN2 variants from pure nephrotic syndrome to a potential chronic, progressive, non-nephrotic renal pathology characterized by thin basement membrane disease and vascular involvement. It emphasizes the value of comprehensive genetic testing for patients with unexplained, familial chronic renal decline.
Objective: Intersectin 2 (ITSN2) is reported to cause hereditary nephrotic syndrome, but the number of cases remains quite small. We observed a case of progressive renal dysfunction and family history for end-stage kidney disease with a known single heterozygous ITSN2 variant. This study aimed to reveal the novel pathological significance of altered ITSN2 expression via a detailed examination.
Alex: So controlled blood pressure didn't explain away the progression. What did the eventual biopsy add?
Sam: It showed a thin basement membrane, part of the filtration barrier in the kidney. It also showed global glomerulosclerosis, meaning complete scarring of individual filtering units. Six of the sixteen units sampled were globally scarred.
Alex: Some scarring occurs with age. What made that amount stand out?
Sam: Using a published age-based comparison, the authors expected about two scarred units in a sample of that size. They also saw prominent changes in small arteries. Their interpretation was that the scarring and vascular changes exceeded what they expected from her age and known risk factors.
Alex: That's a reference comparison, then, not a matched group examined alongside this patient.
Sam: Yes. It helps explain why they investigated further, but it isn't a controlled comparison. She also had obesity and lipid abnormalities, so the report does not present her as free of other possible contributors.
Alex: The thin filtration membrane sounds like a separate clue. Where would that usually send the genetic investigation?
Sam: Toward collagen-related kidney disorders, including Alport syndrome, which affects the kidney's filtration barrier. The authors screened a panel of 121 genes associated with inherited kidney disease. They did not identify causal variants in the usual Alport-related genes or other tested genes known to produce that thin-membrane appearance.
Alex: Not finding the usual explanation doesn't automatically make the remaining variant responsible. What did they actually find?
Sam: A single heterozygous variant in I-T-S-N-two. The same protein change had appeared in earlier nephrotic syndrome reports, but in different genetic settings. In one, both copies carried that change; in another, it appeared alongside a different damaging variant.
Alex: So the prior evidence gives this candidate a reason to be noticed. It doesn't show that one altered copy is enough.
Sam: And the authors explicitly acknowledge that. Under the classification criteria they used, this variant was of uncertain significance. That label means the available evidence did not establish whether it was disease-causing.
Alex: Is there a biological argument connecting this gene to the kidney findings, beyond its appearance in earlier patients?
Sam: There is a proposed connection. The protein helps organize complexes involved in moving material within cells and assembling their internal framework. One form can activate C-D-C-forty-two, a molecular switch that helps regulate that framework.
Alex: And that matters in the cells maintaining the kidney's filtration barrier?
Sam: Yes. The paper cites mouse research in which removing that switch specifically from glomerular epithelial cells caused protein leakage. Those cells help maintain the filter. The authors propose that altered signalling could also affect the basement membrane.
Alex: But did they measure that signalling in this patient's tissue, or demonstrate how her variant changed the protein?
Sam: No such functional demonstration is reported. Reduced activity of the switch is a proposed mechanism, not a measured result in this patient. The connection to membrane thinning remains particularly uncertain.
Alex: There's also the vascular finding. Did the kidney changes turn out to be part of a wider pattern?
Sam: Further examinations found plaques in the carotid arteries and calcification in several large arteries. The authors judged these findings suggestive of accelerated atherosclerosis, meaning plaque-related arterial disease. They considered whether altered signalling might contribute to both vascular and kidney damage.
Alex: That adds another possible phenotype, but also another causal step to establish.
Sam: It does. The paper discusses previous research connecting this signalling system with ageing and vascular disease. But it does not show that the patient's variant caused her arterial changes, or that those changes caused her kidney decline.
Alex: We're left with several observations that might fit together, rather than a demonstrated chain.
Sam: That's my reading. The strongest evidence is the documented combination: progressive dysfunction, unusual tissue findings, family history, and a candidate variant. The weakest link is assigning that combination to the variant itself.
Alex: What missing evidence would have been most informative within this family?
Sam: Testing affected relatives. If the same variant tracked with kidney disease, that could strengthen the proposed association. The authors wanted that information, but relatives were estranged from the patient, so testing could not be performed.
Alex: Without that, the apparent dominant inheritance pattern and the single-copy finding can't actually be connected.
Sam: They remain compatible observations, not a demonstrated genetic relationship. And because this is one patient, the report cannot establish how often this presentation occurs or whether carriers generally face increased risk.
Alex: Given those limits, who should read the full report, and where should they start?
Sam: Researchers working on inherited kidney disease, filtration-barrier biology, or interpretation of uncertain variants. Start with the kidney biopsy and genetic testing sections, then read the discussion's comparison with earlier I-T-S-N-two cases. Keep the uncertain classification and missing family testing beside the proposed mechanism.
Alex: And what should everyone else carry away?
Sam: This case raises a possible new presentation of a previously implicated gene. It does not establish a new cause of kidney failure. A genetic clue can justify a hypothesis without settling a diagnosis.
Alex: Thanks for listening.